Christine Wennerås
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christine Wennerås has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Anna Grankvist
Department of Infectious Diseases, the Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
7 shared publicationsLinda Wass
Department of Clinical Microbiology Sahlgrenska University Hospital Gothenburg Sweden
5 shared publicationsCatharina Lewerin
Department of Hematology and Coagulation Sahlgrenska University Hospital
4 shared publications- Christine Lingblom
Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
4 shared publications Christina Welinder-Olsson
Department of Clinical Microbiology, Sahlgrenska University Hospital, and Department of Infectious Diseases, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
3 shared publicationsChristine Lingblom
Department of Infectious Diseases, the Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
3 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1327-1334
Neoehrlichia mikurensis infection associated with lymphoma or mimicking lymphoma in two cohorts of Swedish patients
Neoehrlichiosis is a zoonotic infectious disease caused by the bacterial species Neoehrlichia (N.) mikurensis. The first case reports of infection caused by this emerging pathogen were published in...
- 4 March 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1327-1334
Open AccessNeoehrlichia mikurensis infection associated with lymphoma or mimicking lymphoma in two cohorts of Swedish patients
Neoehrlichiosis is a zoonotic infectious disease caused by the bacterial species Neoehrlichia (N.) mikurensis. The first case reports of infection caused by this emerging pathogen were published in...
- Open Access
- 5 February 2026
- Published by Wiley in Immunology
- Vol. 178 (2) , 307-317
Latent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B‐Cell Lymphomas Treated With Rituximab
The intracellular, tick‐borne bacterium Neoehrlichia (N.) mikurensis can cause neoehrlichiosis in patients with compromised B‐cell defences, while immunocompetent individuals are frequently healthy carriers of the infection. We hypothesised that N. mikurensis induces latent infections that reactivate when B‐cell immunity is compromised. We tested this hypothesis by determining the incidence of N. mikurensis reactivation in 97 patients with B‐cell lymphomas who were treated with anti‐CD20 antibody therapy (rituximab) and evaluating the presence of N. mikurensis ‐specific T cells in latently infected individuals. Four patients (4%) reactivated N. mikurensis infection and four patients (4%) had asymptomatic infection before the initiation of B‐cell suppression. All eight patients who were infected with N. mikurensis had N. mikurensis ‐specific, perforin‐expressing Th1 and CD8+ T‐cell populations with up‐regulation of CXCL10 and IFN‐γ, in contrast to the noninfected lymphoma patients who lacked these T‐cell subsets. The infected lymphoma patients also had expanded γδ T‐cell populations. This study supports the notion of latent, reactivatable N. mikurensis infections.
- 5 February 2026
- Published by Wiley in Immunology
- Vol. 178 (2) , 307-317
Open AccessLatent Neoehrlichia mikurensis Infections May Be Reactivated in Patients With B‐Cell Lymphomas Treated With Rituximab
The intracellular, tick‐borne bacterium Neoehrlichia (N.) mikurensis can cause neoehrlichiosis in patients with compromised B‐cell defences, while immunocompetent individuals are frequently healthy carriers of the infection. We hypothesised that N. mikurensis induces latent infections that reactivate when B‐cell immunity is compromised. We tested this hypothesis by determining the incidence of N. mikurensis reactivation in 97 patients with B‐cell lymphomas who were treated with anti‐CD20 antibody therapy (rituximab) and evaluating the presence of N. mikurensis ‐specific T cells in latently infected individuals. Four patients (4%) reactivated N. mikurensis infection and four patients (4%) had asymptomatic infection before the initiation of B‐cell suppression. All eight patients who were infected with N. mikurensis had N. mikurensis ‐specific, perforin‐expressing Th1 and CD8+ T‐cell populations with up‐regulation of CXCL10 and IFN‐γ, in contrast to the noninfected lymphoma patients who lacked these T‐cell subsets. The infected lymphoma patients also had expanded γδ T‐cell populations. This study supports the notion of latent, reactivatable N. mikurensis infections.
- Open Access
- 13 August 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (11) , 2083-2092
Ten years of detecting Neoehrlichia mikurensis infections in Sweden: demographic, clinical and inflammatory parameters
Purpose: To increase knowledge about the varied clinical manifestations of human infection with the emerging tick-borne pathogen Neoehrlichia mikurensis. Methods: All patients diagnosed in Sweden with N. mikurensis infection during a 10-year period (2013–2023) were investigated regarding their demographic factors, risk factors, comorbidities, clinical signs and symptoms, and laboratory results. Multivariate models were generated using “Orthogonal Projections to Latent Structures-Discriminant Analysis” to identify clinical and immune parameters associated with N. mikurensis infection. Results: During the 10-year period, 134 patients were diagnosed with N. mikurensis infection, 102 of whom were included in this study. Most of the patients (79%) were immunosuppressed. The main comorbidities were malignant B-cell lymphomas, multiple sclerosis, and rheumatoid arthritis. Rituximab therapy (59%) and splenectomy (14%) featured prominently. All patients resided in the southern tick-endemic part of Sweden, yet one-third of them were diagnosed in wintertime when ticks are inactive. Two asymptomatically infected blood donors were identified but transfusion-transmitted infection was not confirmed. Increased levels of C-reactive protein, orosomucoid, and total IgM in serum were associated with neoehrlichiosis. Previously unreported symptoms such as ankle edema, neck pain, numbness, and sudden deafness were detected in some patients. One case of aplastic anemia partially improved after eradication of the infection. Conclusions: Neoehrlichiosis is a multi-faceted emerging infectious disease.
- 13 August 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (11) , 2083-2092
Open AccessTen years of detecting Neoehrlichia mikurensis infections in Sweden: demographic, clinical and inflammatory parameters
Purpose: To increase knowledge about the varied clinical manifestations of human infection with the emerging tick-borne pathogen Neoehrlichia mikurensis. Methods: All patients diagnosed in Sweden with N. mikurensis infection during a 10-year period (2013–2023) were investigated regarding their demographic factors, risk factors, comorbidities, clinical signs and symptoms, and laboratory results. Multivariate models were generated using “Orthogonal Projections to Latent Structures-Discriminant Analysis” to identify clinical and immune parameters associated with N. mikurensis infection. Results: During the 10-year period, 134 patients were diagnosed with N. mikurensis infection, 102 of whom were included in this study. Most of the patients (79%) were immunosuppressed. The main comorbidities were malignant B-cell lymphomas, multiple sclerosis, and rheumatoid arthritis. Rituximab therapy (59%) and splenectomy (14%) featured prominently. All patients resided in the southern tick-endemic part of Sweden, yet one-third of them were diagnosed in wintertime when ticks are inactive. Two asymptomatically infected blood donors were identified but transfusion-transmitted infection was not confirmed. Increased levels of C-reactive protein, orosomucoid, and total IgM in serum were associated with neoehrlichiosis. Previously unreported symptoms such as ankle edema, neck pain, numbness, and sudden deafness were detected in some patients. One case of aplastic anemia partially improved after eradication of the infection. Conclusions: Neoehrlichiosis is a multi-faceted emerging infectious disease.
- Open Access
- 26 April 2023
- Published by Wiley in Journal of Immunology Research
- Vol. 2023, 1-11
Antieosinophil Antibodies Alone or in Combination with Antineutrophil Cytoplasmic Antibodies (ANCA) Detected in Different Autoimmune Conditions
Circulating antieosinophil antibodies (AEOSA) have been associated with various autoimmune conditions affecting the liver, kidneys, lungs, and joints but are not part of routine clinical diagnostics. While analyzing human sera for antineutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence (IIF) on granulocytes, 0.8% of analyzed samples were found to be reactive with eosinophils. Our aim was to determine the diagnostic relevance and antigenic specificity of AEOSA. AEOSA were seen either in combination with an myeloperoxidase (MPO)-positive p-ANCA (44%; AEOSA+/ANCA+) or on their own (56%; AEOSA+/ANCA−). AEOSA/ANCA positivity was seen in patients with thyroid disease (44%) or vasculitis (31%), while AEOSA+/ANCA− pattern was more common in patients with autoimmune disorders of the gastrointestinal tract and/or liver. Eosinophil peroxidase (EPX) was the main target recognized in 66% of the AEOSA+ sera by enzyme-linked immunosorbent assay (ELISA). Eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) were also identified as target antigens but less frequently and only in combination with EPX. In conclusion, we confirmed that EPX is a major target of AEOSA, illustrating the high antigenic potential of EPX. Our results also demonstrate the presence of concomitant AEOSA/ANCA positivity in a defined patient group. Further research should aim to elucidate the association of AEOSA with autoimmunity.
- 26 April 2023
- Published by Wiley in Journal of Immunology Research
- Vol. 2023, 1-11
Open AccessAntieosinophil Antibodies Alone or in Combination with Antineutrophil Cytoplasmic Antibodies (ANCA) Detected in Different Autoimmune Conditions
Circulating antieosinophil antibodies (AEOSA) have been associated with various autoimmune conditions affecting the liver, kidneys, lungs, and joints but are not part of routine clinical diagnostics. While analyzing human sera for antineutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence (IIF) on granulocytes, 0.8% of analyzed samples were found to be reactive with eosinophils. Our aim was to determine the diagnostic relevance and antigenic specificity of AEOSA. AEOSA were seen either in combination with an myeloperoxidase (MPO)-positive p-ANCA (44%; AEOSA+/ANCA+) or on their own (56%; AEOSA+/ANCA−). AEOSA/ANCA positivity was seen in patients with thyroid disease (44%) or vasculitis (31%), while AEOSA+/ANCA− pattern was more common in patients with autoimmune disorders of the gastrointestinal tract and/or liver. Eosinophil peroxidase (EPX) was the main target recognized in 66% of the AEOSA+ sera by enzyme-linked immunosorbent assay (ELISA). Eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) were also identified as target antigens but less frequently and only in combination with EPX. In conclusion, we confirmed that EPX is a major target of AEOSA, illustrating the high antigenic potential of EPX. Our results also demonstrate the presence of concomitant AEOSA/ANCA positivity in a defined patient group. Further research should aim to elucidate the association of AEOSA with autoimmunity.
- Open Access
- 17 January 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (3) , 480-488
Infection with Neoehrlichia mikurensis promotes the development of malignant B‐cell lymphomas
Summary: The tick‐borne pathogen Neoehrlichia (N.) mikurensis is implicated in persistent infection of the vascular endothelium. B cells are crucial for the host defence to this infection. Chronic stimulation of B cells may result in B‐cell transformation and lymphoma. Five patients with malignant B‐cell lymphoma and concomitant N. mikurensis infection were investigated regarding clinical picture, lymphoma subtype, B‐cell lymphoma immunophenotype and IGHV (variable region of the immunoglobulin heavy) gene repertoire. Three of the five patients improved markedly and ceased lymphoma treatment after doxycycline treatment to eliminate N. mikurensis. Sequencing the B‐cell lymphoma IGHV genes revealed preferred usage of the IGHV1 (IGHV1‐2, and ‐69) and IGHV3 (IGHV3‐15, ‐21, ‐23) families. In conclusion, N. mikurensis infection may drive the development of malignant B‐cell lymphomas. Eradication of the pathogen appears to induce remission with apparent curing of the lymphoma in some cases.
- 17 January 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (3) , 480-488
Open AccessInfection with Neoehrlichia mikurensis promotes the development of malignant B‐cell lymphomas
Summary: The tick‐borne pathogen Neoehrlichia (N.) mikurensis is implicated in persistent infection of the vascular endothelium. B cells are crucial for the host defence to this infection. Chronic stimulation of B cells may result in B‐cell transformation and lymphoma. Five patients with malignant B‐cell lymphoma and concomitant N. mikurensis infection were investigated regarding clinical picture, lymphoma subtype, B‐cell lymphoma immunophenotype and IGHV (variable region of the immunoglobulin heavy) gene repertoire. Three of the five patients improved markedly and ceased lymphoma treatment after doxycycline treatment to eliminate N. mikurensis. Sequencing the B‐cell lymphoma IGHV genes revealed preferred usage of the IGHV1 (IGHV1‐2, and ‐69) and IGHV3 (IGHV3‐15, ‐21, ‐23) families. In conclusion, N. mikurensis infection may drive the development of malignant B‐cell lymphomas. Eradication of the pathogen appears to induce remission with apparent curing of the lymphoma in some cases.
- Open Access
- 20 December 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (1) , 3
Fungal Tracheobronchitis in Lung Transplant Recipients: Incidence and Utility of Diagnostic Markers
Fungal tracheobronchitis caused by Aspergillus and Candida spp. is a recognized complication after lung transplantation, but knowledge of the incidence of Candida tracheobronchitis is lacking. The diagnosis relies on fungal cultures in bronchoalveolar lavage fluid (BALF), but cultures have low specificity. We aimed to evaluate the one-year incidence of fungal tracheobronchitis after lung transplantation and to assess the utility of diagnostic markers in serum and BALF to discriminate fungal tracheobronchitis from colonization. Ninety-seven consecutively included adult lung-transplant recipients were prospectively followed. BALF and serum samples were collected at 1, 3 and 12 months after transplantation and analyzed for betaglucan (serum and BALF), neutrophils (BALF) and galactomannan (BALF). Fungal tracheobronchitis was defined according to consensus criteria, modified to include Candida as a mycologic criterion. The cumulative one-year incidence of Candida and Aspergillus tracheobronchitis was 23% and 16%, respectively. Neutrophils of >75% of total leukocytes in BALF had 92% specificity for Candida tracheobronchitis. The area under the ROC curves for betaglucan and galactomannan in BALF to discriminate Aspergillus tracheobronchitis from colonization or no fungal infection were high (0.86 (p < 0.0001) and 0.93 (p < 0.0001), respectively). To conclude, the one-year incidence of fungal tracheobronchitis after lung transplantation was high and dominated by Candida spp. Diagnostic markers in BALF could be useful to discriminate fungal colonization from tracheobronchitis.
- 20 December 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (1) , 3
Open AccessFungal Tracheobronchitis in Lung Transplant Recipients: Incidence and Utility of Diagnostic Markers
Fungal tracheobronchitis caused by Aspergillus and Candida spp. is a recognized complication after lung transplantation, but knowledge of the incidence of Candida tracheobronchitis is lacking. The diagnosis relies on fungal cultures in bronchoalveolar lavage fluid (BALF), but cultures have low specificity. We aimed to evaluate the one-year incidence of fungal tracheobronchitis after lung transplantation and to assess the utility of diagnostic markers in serum and BALF to discriminate fungal tracheobronchitis from colonization. Ninety-seven consecutively included adult lung-transplant recipients were prospectively followed. BALF and serum samples were collected at 1, 3 and 12 months after transplantation and analyzed for betaglucan (serum and BALF), neutrophils (BALF) and galactomannan (BALF). Fungal tracheobronchitis was defined according to consensus criteria, modified to include Candida as a mycologic criterion. The cumulative one-year incidence of Candida and Aspergillus tracheobronchitis was 23% and 16%, respectively. Neutrophils of >75% of total leukocytes in BALF had 92% specificity for Candida tracheobronchitis. The area under the ROC curves for betaglucan and galactomannan in BALF to discriminate Aspergillus tracheobronchitis from colonization or no fungal infection were high (0.86 (p < 0.0001) and 0.93 (p < 0.0001), respectively). To conclude, the one-year incidence of fungal tracheobronchitis after lung transplantation was high and dominated by Candida spp. Diagnostic markers in BALF could be useful to discriminate fungal colonization from tracheobronchitis.
- 23 May 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (8) , 1335-1337
Multivariate modeling of eosinophil markers and other cellular immune parameters associated with the development of chronic graft-versus-host disease
- 23 May 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (8) , 1335-1337
Multivariate modeling of eosinophil markers and other cellular immune parameters associated with the development of chronic graft-versus-host disease
- Open Access
- 22 January 2022
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 35 (7)
Validation of the Swedish Watson Dysphagia Scale for adult patients with eosinophilic esophagitis
Background: The Swedish Watson Dysphagia Scale (S-WDS) has been used to assess dysphagia in patients with eosinophilic esophagitis (EoE) but has not been validated for this patient group. The aim of this study was to validate the S-WDS for adult patients with EoE. Methods: Ninety-seven Swedish adult patients with EoE and 97 controls without dysphagia filled out the S-WDS, the Swedish Eosinophilic Esophagitis Activity Index (S-EEsAI) and a set of supplementary questions. The reliability of the S-WDS was evaluated using Cronbach’s alpha, Pearson correlation of items and total score, and test–retest analysis (n = 29). Validity was investigated using Spearman correlations of the S-WDS items, S-EEsAI domains and a self-assessment score, and by investigating floor and ceiling effects. Results: The Cronbach’s alpha of the S-WDS was 0.77 and all items demonstrated moderate to strong correlation to the S-WDS score (r = 0.40–0.81) indicative of sufficient reliability of the instrument. In addition, the test–retest results reflected excellent reliability with an intraclass correlation coefficient of 0.85 for the S-WDS score. Adequate validity of the instrument was demonstrated, the S-WDS score correlated moderately with the self-assessment score and with 4/6 S-EEsAI domains, and strongly with the remaining two domains. Floor effects were more common for liquids and soft-textured foods and ceiling effects increased with increasing food consistency. The S-WDS scores of the patient group were significantly different from those of the nondysphagia control group (P < 0.001). Conclusion: The S-WDS instrument is an appropriate and valid instrument for assessment of dysphagia in patients with EoE.
- 22 January 2022
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 35 (7)
Open AccessValidation of the Swedish Watson Dysphagia Scale for adult patients with eosinophilic esophagitis
Background: The Swedish Watson Dysphagia Scale (S-WDS) has been used to assess dysphagia in patients with eosinophilic esophagitis (EoE) but has not been validated for this patient group. The aim of this study was to validate the S-WDS for adult patients with EoE. Methods: Ninety-seven Swedish adult patients with EoE and 97 controls without dysphagia filled out the S-WDS, the Swedish Eosinophilic Esophagitis Activity Index (S-EEsAI) and a set of supplementary questions. The reliability of the S-WDS was evaluated using Cronbach’s alpha, Pearson correlation of items and total score, and test–retest analysis (n = 29). Validity was investigated using Spearman correlations of the S-WDS items, S-EEsAI domains and a self-assessment score, and by investigating floor and ceiling effects. Results: The Cronbach’s alpha of the S-WDS was 0.77 and all items demonstrated moderate to strong correlation to the S-WDS score (r = 0.40–0.81) indicative of sufficient reliability of the instrument. In addition, the test–retest results reflected excellent reliability with an intraclass correlation coefficient of 0.85 for the S-WDS score. Adequate validity of the instrument was demonstrated, the S-WDS score correlated moderately with the self-assessment score and with 4/6 S-EEsAI domains, and strongly with the remaining two domains. Floor effects were more common for liquids and soft-textured foods and ceiling effects increased with increasing food consistency. The S-WDS scores of the patient group were significantly different from those of the nondysphagia control group (P < 0.001). Conclusion: The S-WDS instrument is an appropriate and valid instrument for assessment of dysphagia in patients with EoE.
- Open Access
- 12 October 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (10) , 2138
Neoehrlichia mikurensis Causing Thrombosis and Relapsing Fever in a Lymphoma Patient Receiving Rituximab
Neoehrlichia (N.) mikurensis, an intracellular tick-borne bacterium not detected by routine blood culture, is prevalent in ticks in Scandinavia, Central Europe and Northern Asia, and may cause long-standing fever, nightly sweats, migrating pain, skin rashes and thromboembolism, especially in patients treated with rituximab. The multiple symptoms may raise suspicion of both infection, inflammation and malignancy, and lead in most cases to extensive medical investigations across many medical specialist areas and a delay of diagnosis. We describe a complex, albeit typical, case of neoehrlichiosis in a middle-aged splenectomised male patient with a malignant lymphoma, receiving treatment with rituximab. The multifaceted clinical picture associated with this tick-borne disease is addressed, and longitudinal clinical and laboratory data, as well as imaging, are provided. Longstanding relapsing fever in combination with thrombosis in superficial and deep veins in an immunocompromised patient living in a tick-endemic region should raise the suspicion of the emerging tick-borne disease neoehrlichiosis. Given the varied clinical presentation and the risk of delay in diagnosis and treatment, we believe it is important to raise clinicians’ awareness of this emerging infection, which is successfully treated with doxycycline.
- 12 October 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (10) , 2138
Open AccessNeoehrlichia mikurensis Causing Thrombosis and Relapsing Fever in a Lymphoma Patient Receiving Rituximab
Neoehrlichia (N.) mikurensis, an intracellular tick-borne bacterium not detected by routine blood culture, is prevalent in ticks in Scandinavia, Central Europe and Northern Asia, and may cause long-standing fever, nightly sweats, migrating pain, skin rashes and thromboembolism, especially in patients treated with rituximab. The multiple symptoms may raise suspicion of both infection, inflammation and malignancy, and lead in most cases to extensive medical investigations across many medical specialist areas and a delay of diagnosis. We describe a complex, albeit typical, case of neoehrlichiosis in a middle-aged splenectomised male patient with a malignant lymphoma, receiving treatment with rituximab. The multifaceted clinical picture associated with this tick-borne disease is addressed, and longitudinal clinical and laboratory data, as well as imaging, are provided. Longstanding relapsing fever in combination with thrombosis in superficial and deep veins in an immunocompromised patient living in a tick-endemic region should raise the suspicion of the emerging tick-borne disease neoehrlichiosis. Given the varied clinical presentation and the risk of delay in diagnosis and treatment, we believe it is important to raise clinicians’ awareness of this emerging infection, which is successfully treated with doxycycline.
- Open Access
- 3 June 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (5) , 1556-1564
Patient-Reported Outcomes and Blood-Based Parameters Identify Response to Treatment in Eosinophilic Esophagitis
Background Noninvasive methods to assess treatment response in eosinophilic esophagitis are needed. Aims Our aim was to determine whether a blood-based biomarker panel centered on immune parameters could identify histologic response to treatment in eosinophilic esophagitis patients. Methods A pilot study involving adult patients with active eosinophilic esophagitis recruited at two Ear, Nose, Throat clinics in Sweden was designed. The patients (n = 20) donated blood and esophageal biopsies and filled in three questionnaires before and after a 2-month course of topical corticosteroids. Blood samples were analyzed for absolute levels of granulocytes and T cells and the fractions of eosinophils expressing 10 different surface markers by flow cytometry. All data were analyzed by multivariate methods of pattern recognition. Results Multivariate modeling revealed that a combination of 13 immune parameters and 10 patient-reported outcome scores were required to create a model capable of separating responders (n = 15) from non-responders (n = 5). Questions regarding symptoms of esophageal dysfunction and capacity to eat certain foods from two of the questionnaires were discriminatory in the multivariate model, as were absolute counts of T cells, eosinophils, and eosinophil expression of activation markers and cell adhesion molecules. Conclusions A combination of blood-based immune parameters and directed questions may prove helpful to monitor response to treatment, perhaps reducing the need for repeat endoscopies in eosinophilic esophagitis patients in the future.
- 3 June 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (5) , 1556-1564
Open AccessPatient-Reported Outcomes and Blood-Based Parameters Identify Response to Treatment in Eosinophilic Esophagitis
Background Noninvasive methods to assess treatment response in eosinophilic esophagitis are needed. Aims Our aim was to determine whether a blood-based biomarker panel centered on immune parameters could identify histologic response to treatment in eosinophilic esophagitis patients. Methods A pilot study involving adult patients with active eosinophilic esophagitis recruited at two Ear, Nose, Throat clinics in Sweden was designed. The patients (n = 20) donated blood and esophageal biopsies and filled in three questionnaires before and after a 2-month course of topical corticosteroids. Blood samples were analyzed for absolute levels of granulocytes and T cells and the fractions of eosinophils expressing 10 different surface markers by flow cytometry. All data were analyzed by multivariate methods of pattern recognition. Results Multivariate modeling revealed that a combination of 13 immune parameters and 10 patient-reported outcome scores were required to create a model capable of separating responders (n = 15) from non-responders (n = 5). Questions regarding symptoms of esophageal dysfunction and capacity to eat certain foods from two of the questionnaires were discriminatory in the multivariate model, as were absolute counts of T cells, eosinophils, and eosinophil expression of activation markers and cell adhesion molecules. Conclusions A combination of blood-based immune parameters and directed questions may prove helpful to monitor response to treatment, perhaps reducing the need for repeat endoscopies in eosinophilic esophagitis patients in the future.